While patritumab itself as a monotherapy did not advance in CRC treatment, its development provided critical insights into HER3 biology and therapeutic resistance mechanisms, shaping the direction for next-generation HER3-targeted strategies. Here, ERBB3 is linked to colorectal carcinoma.